基于生物信息学和荟萃分析的PSMD14在癌症中的临床病理及预后意义
The clinicopathological and prognostic significance of PSMD14 in cancers based on bioinformatics and meta-analysis.
作者信息
Dong Shu-Yi, Ding Shuxin, Meng Zhen, Zou Bo
机构信息
Department of Oral & Maxillofacial Surgery, Liaocheng People's Hospital, Medical College of Liaocheng University, Liaocheng, Shandong, P. R. China.
Key Laboratory of Oral Maxillofacial-Head & Neck medical biology of Shandong Province, Liaocheng People's Hospital, Liaocheng, Shandong, P. R. China.
出版信息
Future Sci OA. 2024 Dec 31;10(1):2409054. doi: 10.1080/20565623.2024.2409054. Epub 2024 Oct 11.
To evaluate the clinic-pathological features and prognostic value regarding PSMD14 in cancers. Literature was gathered from public databases until 22 June 2023 to analyze data on survival rates and clinicopathological characteristics associated with PSMD14. TCGA and GEO data were also utilized for validation. Eight reports on seven types of tumors showed that high PSMD14 expression was linked to poorer overall survival and disease-free survival. PSMD14 expression also correlated with larger tumor size, differentiation and metastasis, as well as the effectiveness of various chemotherapy drugs. PSMD14 could serve as a potential biomarker of poor prognosis in cancers, including lung cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer and hepatocellular carcinoma.
评估PSMD14在癌症中的临床病理特征及预后价值。从公共数据库收集截至2023年6月22日的文献，以分析与PSMD14相关的生存率和临床病理特征数据。还利用TCGA和GEO数据进行验证。八项关于七种肿瘤类型的报告显示，PSMD14高表达与较差的总生存期和无病生存期相关。PSMD14表达还与更大的肿瘤大小、分化和转移以及各种化疗药物的疗效相关。PSMD14可作为包括肺癌、头颈部鳞状细胞癌、卵巢癌、乳腺癌和肝细胞癌在内的癌症预后不良的潜在生物标志物。
Zotero 插件